Amicus Therapeutics, Inc. (FOLD)

NASDAQ: FOLD · IEX Real-Time Price · USD
10.00
-0.09 (-0.89%)
Jun 24, 2024, 4:00 PM EDT - Market closed
-0.89%
Market Cap 2.96B
Revenue (ttm) 423.49M
Net Income (ttm) -147.07M
Shares Out 296.20M
EPS (ttm) -0.49
PE Ratio n/a
Forward PE 1,669.60
Dividend n/a
Ex-Dividend Date n/a
Volume 3,162,038
Open 10.16
Previous Close 10.09
Day's Range 9.98 - 10.38
52-Week Range 9.02 - 14.57
Beta 0.73
Analysts Buy
Price Target 17.14 (+71.4%)
Earnings Date Aug 6, 2024

About FOLD

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and Glaxo... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 31, 2007
Employees 517
Stock Exchange NASDAQ
Ticker Symbol FOLD
Full Company Profile

Financial Performance

In 2023, FOLD's revenue was $399.36 million, an increase of 21.30% compared to the previous year's $329.23 million. Losses were -$151.58 million, -35.92% less than in 2022.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for FOLD stock is "Buy." The 12-month stock price forecast is $17.14, which is an increase of 71.40% from the latest price.

Price Target
$17.14
(71.40% upside)
Analyst Consensus: Buy
Stock Forecasts

News

In NCLA Amicus Win, Supreme Court Overturns NLRB-Specific Preliminary Injunction Standard

Starbucks Corporation v. M. Kathleen McKinney, Regional Director of Region 15 of the NLRB Starbucks Corporation v. M. Kathleen McKinney, Regional Director of Region 15 of the NLRB

11 days ago - GlobeNewsWire

In NCLA Amicus Win, Tenth Circuit Clears Path to Toppling Intrusive Dog Kennel Inspection Regime

Scott Johnson, Harlene Hoyt, Covey Find Kennel, LLC v. Justin Smith, D.V.M., in his official capacity as Animal Health Commissioner at the Kansas Department of Agriculture Scott Johnson, Harlene Hoyt,...

13 days ago - GlobeNewsWire

In NCLA Amicus Win, Fifth Circuit Topples SEC's Unlawful Effort to Regulate Private Funds

National Association of Private Fund Managers, et al. v. Securities and Exchange Commission National Association of Private Fund Managers, et al. v. Securities and Exchange Commission

19 days ago - GlobeNewsWire

Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Health...

19 days ago - GlobeNewsWire

Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates

1Q 2024 Total Revenue of $110.4M, a 28% Increase Year-over-Year Guiding to Full-Year 2024 Total Revenue Growth of 25%-30% at CER Raising Full-Year 2024 Galafold ® Guidance on Continued Strong Demand S...

6 weeks ago - GlobeNewsWire

Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference

PRINCETON, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2024 Health Care Confere...

6 weeks ago - GlobeNewsWire

Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024

PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 9, 2024, at 8:...

7 weeks ago - GlobeNewsWire

Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report

PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for r...

3 months ago - GlobeNewsWire

Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024

PRINCETON, N.J., March 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences ...

4 months ago - GlobeNewsWire

Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates

2023 Total Revenue of $399.4M, a 21% Increase Year-over-Year Strong Patient Demand Continues for Pombiliti ™ + Opfolda ™ in the U.S., U.K., and Germany Projecting 2024 Galafold ® Revenue Growth of 11-...

4 months ago - GlobeNewsWire

Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024

PRINCETON, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 28, 202...

4 months ago - GlobeNewsWire

Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™

- Award Recognizes Approval of Amicus Therapeutics' Two-component Therapy for the Treatment of Late-onset Pompe Disease - - Award Recognizes Approval of Amicus Therapeutics' Two-component Therapy for ...

4 months ago - GlobeNewsWire

Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024

PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and 11 posters across its development programs will be included at the...

5 months ago - GlobeNewsWire

Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook

2023 Total Revenue of ~$399.4M, a 21% Increase Year-Over-Year >2,400 People Living with Fabry Disease on Galafold ® Following a Year of Increased Demand Expecting 2024 Galafold Revenue Growth of 11-16...

6 months ago - GlobeNewsWire

Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

PRINCETON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 42nd Annual J.P....

6 months ago - GlobeNewsWire

Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO

Crowley to Step Down from Amicus Board of Directors in March 2024  and Become Amicus Chairman Emeritus

7 months ago - GlobeNewsWire

Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates

3Q 2023 Total Revenue of $103.5M, a 27% Increase Year-Over-Year and 22% at CER Galafol d ® Quarterly Revenue Surpasses $100M for the First Time Increasing FY 2023 Galafol d ® Revenue Growth Guidance t...

8 months ago - GlobeNewsWire

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023

PRINCETON, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences i...

8 months ago - GlobeNewsWire

Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023

PRINCETON, N.J., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 8, 2023...

8 months ago - GlobeNewsWire

Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023

PRINCETON, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and four posters highlighting its development program for Pompe diseas...

9 months ago - GlobeNewsWire

Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration

Refinancing of Current $400M Debt at Lower Cost and Improved Amortization Schedule Blackstone to also Purchase $30M of Amicus Common Stock PRINCETON, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Amicus The...

9 months ago - GlobeNewsWire

WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease

WUXI, China , Oct. 1, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic pa...

9 months ago - PRNewsWire

US FDA approves Amicus Therapeutics' muscle disorder treatment

Amicus Therapeutics said on Thursday the U.S. Food and Drug Administration (FDA) had approved its therapy to treat a muscle disorder called Pompe disease.

9 months ago - Reuters

Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease

Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults Living with Late-onset Pompe Disease Amicus Th...

9 months ago - GlobeNewsWire

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023

PHILADELPHIA, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in ...

10 months ago - GlobeNewsWire